anticoagulant_guidelines
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| anticoagulant_guidelines [2026/08/31 10:14] – [general anticoagulation guidelines] gary1 | anticoagulant_guidelines [2026/08/31 10:15] (current) – [Before initiating antithrombotic Rx] gary1 | ||
|---|---|---|---|
| Line 18: | Line 18: | ||
| <note tip> | <note tip> | ||
| ***DOACs are now the preferred antithrombotic Rx over warfarin for most patients with non-valvular AF, DVT or PE** | ***DOACs are now the preferred antithrombotic Rx over warfarin for most patients with non-valvular AF, DVT or PE** | ||
| + | *the ARISTOTLE trial compared apixaban with warfarin and showed it was 21% better at reducing stroke, had 30% lower incidence of major bleeding, and reduced all-cause mortality by 11% | ||
| </ | </ | ||
anticoagulant_guidelines.txt · Last modified: 2026/08/31 10:15 by gary1